Last Updated on October 9, 2024 by The Health Master
The National Pharmaceutical Pricing Authority (NPPA) has extended the last date for filing statutory forms related to details of price lists and quarterly returns prescribed under the Drugs (Prices Control) Order, 2013 for drugs and medical devices vide its office memorandum dt 21-10-2022.
The move comes after the Authority received several representations from the industry requesting an extension of the last date for filing the statutory forms as under:
- Form III (for submission of quarterly returns in respect of production/import and sale data for drugs under the National List of Essential Medicines),
- Form V (which is an intimation about the Maximum Retail Price change of scheduled and non-scheduled drugs),
- Form VI (which is to intimate the Authority regarding the MRP change of medical devices).
According to an office memo from the Authority, there have been a number of requests for extensions of the due date for submitting the statutory Forms III, V, and VI as required by DPCO, 2013 in the integrated Pharmaceutical Database Management System (IPDMS) 2.0.
The authority has examined the matter and the time limit has been extended, said the OM with further details.
While the data under Form III has to be submitted within fifteen days from the end of the quarter, as per the rules, for the quarter ending September 2022, it can be filed up to December 31, 2022.
Similar to this, instead of the previous deadline of fifteen days from the date of price revision, Form V can now be filed up until December 31, 2022, for any MRP revision carried out between August 1 and December 15, 2022.
According to the price regulation, Form VI, which was added by the Department of Pharmaceuticals through an order on July 20, 2021, must be submitted within fifteen days of a price revision for the notification of a change in the MRP of medical devices.
The NPPA, through the office memorandum, stated that for any MRP revision done between August 1 and December 15, 2022, Form VI can be filed up to December 31, 2022.
According to reports, the NPPA has in the past also issued orders extending the time limit for submission of the forms related to the production, sales, and price data for drugs and medical devices in response to requests from the industry.
The NPPA has implemented the IPDMS 2.0 to collect online data from pharmaceutical manufacturers in order to monitor and control the costs of pharmaceuticals and medical devices and to guarantee their accessibility and affordability in the nation.
Latest on National Pharmaceutical Pricing Authority (NPPA)
Latest notifications – DPCO / NPPA
Latest Notifications: EC Act (Essential Commodities Act)
FAQs – On DPCO: Drugs (Prices Control) Order, 2013
USFDA gives approval to this Blood Cancer therapy
NPPA fixes retail price for diabetes drug combination Dapagliflozin & Sitagliptin
USFDA grants final approval for Micafungin for injection
DTAB ratifies Rule 46 of Medical Devices Rules, 2017
Dove shampoos recalled due to this reason
USFDA completes inspection of Alembic with no observations
PCI: Pharma D automatically eligible for posts meant for B Pharma, D Pharma
Drug recall: These products recalled by Dr Reddy’s, Cipla, and Aurobindo
Drug recall: Sodium Bicarbonate Injection recalled due to this reason
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
